GW Pharmaceuticals PLC (NASDAQ:GWPH) has received an average rating of “Buy” from the twelve brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $146.06.

A number of research analysts have weighed in on the company. ValuEngine lowered GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Maxim Group lowered GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating and set a $61.00 price target on the stock. in a research note on Tuesday, August 8th. BidaskClub lowered GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $124.00 price target on shares of GW Pharmaceuticals PLC in a research note on Friday, October 6th. Finally, Cowen and Company reissued an “outperform” rating and set a $165.00 price target on shares of GW Pharmaceuticals PLC in a research note on Monday, October 2nd.

TRADEMARK VIOLATION WARNING: “GW Pharmaceuticals PLC (GWPH) Receives Consensus Rating of “Buy” from Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/11/gw-pharmaceuticals-plc-gwph-receives-consensus-rating-of-buy-from-analysts.html.

Hedge funds have recently added to or reduced their stakes in the company. Blair William & Co. IL acquired a new stake in shares of GW Pharmaceuticals PLC during the 1st quarter worth $207,000. Victory Capital Management Inc. increased its holdings in shares of GW Pharmaceuticals PLC by 9.2% during the 2nd quarter. Victory Capital Management Inc. now owns 308,945 shares of the biopharmaceutical company’s stock worth $30,971,000 after buying an additional 25,920 shares during the last quarter. Eqis Capital Management Inc. increased its holdings in shares of GW Pharmaceuticals PLC by 23.3% during the 2nd quarter. Eqis Capital Management Inc. now owns 2,899 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 547 shares during the last quarter. HighTower Advisors LLC increased its holdings in shares of GW Pharmaceuticals PLC by 10.3% during the 1st quarter. HighTower Advisors LLC now owns 2,044 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 191 shares during the last quarter. Finally, Alliancebernstein L.P. increased its holdings in shares of GW Pharmaceuticals PLC by 11.0% during the 2nd quarter. Alliancebernstein L.P. now owns 317,956 shares of the biopharmaceutical company’s stock worth $31,875,000 after buying an additional 31,481 shares during the last quarter. Institutional investors and hedge funds own 75.07% of the company’s stock.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded up 1.67% during trading on Wednesday, reaching $112.91. The company had a trading volume of 186,153 shares. The firm’s market capitalization is $2.86 billion. The firm’s 50 day moving average price is $107.17 and its 200 day moving average price is $107.94. GW Pharmaceuticals PLC has a 12 month low of $92.65 and a 12 month high of $136.95.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $2.10 million. During the same period in the prior year, the company earned ($0.05) EPS. Equities analysts predict that GW Pharmaceuticals PLC will post ($5.94) EPS for the current year.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.